Relief Cardiovascular
Relief Cardiovascular is a privately-held medical device company developing the Relief System, the world's first transcatheter preload modulating implant that autonomously monitors hemodynamics and modulates renal vein pressures to treat diuretic-resistant heart failure patients in international cardiac centers.
- Company typePrivate
- Founded2022
- HeadquartersCosta Mesa, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Relief Cardiovascular does
Relief Cardiovascular is a privately-held medical device company founded in 2022 and headquartered in Costa Mesa, California, developing the Relief System — described as the world's first transcatheter preload modulating implant for heart failure management. The implant is delivered via a transcatheter approach into the inferior vena cava and combines permanent preload modulation with autonomous hemodynamic monitoring, enabling adjustment of renal vein pressures and decongestion in patients whose heart failure is inadequately managed by diuretics. The company targets diuretic-resistant heart failure patients globally, addressing persistently elevated pressures, recurrent hospitalizations, and poor long-term outcomes not served by temporary catheters or pharmaceutical regimens.
The Relief System is the company's sole product in clinical development. The first-generation device entered outside-United-States (OUS) clinical investigation in September 2025, and positive 90-day first-in-human results demonstrating procedural safety, accurate hemodynamic sensing, sustained renal flow, and reduced hospitalizations were reported in March 2026. Relief Cardiovascular has assembled a team with deep experience in heart valve, active implant, and catheter-based technology development, backed by cardiovascular-focused investors including Broadview Ventures, Advent Life Sciences, Good Growth Capital, and Heartwork Capital following a $12 million Series A in January 2025. The company received the Jon DeHaan Foundation Award for Innovation in Cardiology at TCT 2025.
Relief Cardiovascular operates a pre-commercial business model with no current revenue. Its intended revenue stream is hardware sales of the Class III implantable Relief System and associated procedural kits to tertiary and quaternary cardiac centers upon regulatory approval, distributed through a direct sales force targeting interventional cardiologists and heart failure specialists. The device is explicitly not available in the United States for clinical trials or commercialization, positioning the company to pursue international regulatory and clinical pathways first before entering the US market.
Relief Cardiovascular firmographics
Firmographics- Name
- Relief Cardiovascular
- Legal name
- Relief Cardiovascular
- Website
- https://reliefcardio.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Relief Cardiovascular is a privately-held medical device company developing the Relief System, the world's first transcatheter preload modulating implant that autonomously monitors hemodynamics and modulates renal vein pressures to treat diuretic-resistant heart failure patients in international cardiac centers.
- Ownership category
- akta.pro rank
Relief Cardiovascular industry classification
Industry- Product category
- Interventional Cardiology Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
- akta.pro secondary industries
- Interventional Cardiology (PCI/Structural Heart) (HLAKABAB), Heart Failure & Transplant Cardiology (HLAKABAD)
Keywords
Where Relief Cardiovascular is headquartered
LocationHeadquarters
- HQ city
- Costa Mesa
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Relief Cardiovascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Transcatheter Implant Sales: Relief Cardiovascular will generate revenue through the sale of its Relief System transcatheter implants to hospitals and cardiac centers upon regulatory approval. As a Class III implantable medical device, each unit sale will involve the device itself as well as associated procedural kits and accessories. Revenue is expected to be procedural/hospital-based, similar to other interventional cardiology devices such as TAVR valves or ICD/pacemaker leads.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Relief Cardiovascular product offering
Product offeringCore offering
Relief Cardiovascular develops the Relief System, the world's first transcatheter preload modulating implant for heart failure management. The Class III implantable medical device is delivered minimally invasively into the inferior vena cava and combines autonomous hemodynamic monitoring with permanent venous return modulation to lower renal vein pressures, enhance diuresis and decongestion, and reduce heart failure hospitalizations in diuretic-resistant patients.
Product overview
Relief Cardiovascular offers a single unified product: the Relief System, a first-generation transcatheter implant for heart failure management. This transcatheter preload modulating implant provides autonomous hemodynamic monitoring and enables modulation of venous return to improve perfusion and decongestion in heart failure patients who are inadequately served by existing diuretic therapies.
Differentiator
Problem solved
Functional benefit
Products and services
- Relief System The world's first transcatheter preload modulating implant designed for heart failure management. The system provides autonomous hemodynamic monitoring paired with the ability to modulate venous return, enabling improved perfusion and decongestion for heart failure patients with inadequate response to diuretics. It is delivered via transcatheter (minimally invasive) implant into the inferior vena cava and can be personalized, monitored, and adjusted over time. The target users are interventional cardiologists and heart failure specialists treating diuretic-resistant heart failure patients at tertiary/quaternary cardiac centers. Note: The Relief System is not available in the USA for clinical trials or for commercialization.
Quantifiable outcome
- Reduction in heart failure hospitalizations at 90 days in first-in-human study
- +3 more outcomes
Companies that use Relief Cardiovascular
Customer profileSegments1 record
Ideal customer profiles1 record
Relief Cardiovascular technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Relief Cardiovascular partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
Relief Cardiovascular competitors and assessment
Company assessmentDirect peers
- Corvia Medical: Corvia Medical is developing the Corvia Atrial Shunt, a transcatheter interatrial shunt device for heart failure with preserved or reduced ejection fraction. It is a direct peer in the emerging transcatheter implantable heart failure device category, targeting the same HF patient population with a different hemodynamic mechanism.
- Procyrion: Procyrion is developing the Aortix percutaneous mechanical circulatory support device, a transcatheter pump targeting heart failure. It is comparable to Relief Cardiovascular as a venture-stage company pursuing novel transcatheter devices that directly target hemodynamics in decompensated or chronic heart failure patients.
- WhiteSwell: WhiteSwell is developing an IVC-based therapy for acute heart failure decongestion, making it the most directly comparable company to Relief Cardiovascular in terms of mechanism (caval flow/preload modulation) and target patient population (congestive HF). The key contrast is that WhiteSwell's approach has been temporary catheters while Relief is pursuing a permanent implant.
- Ancora Heart: Ancora Heart is developing the AccuCinch transcatheter ventricular restoration system for heart failure patients. It is a directly comparable transcatheter implantable heart failure device company, also at early-to-mid clinical stages, targeting the same HF population via a different ventricular remodeling approach.
- Axon Therapies: Axon Therapies is developing a transcatheter splanchnic nerve ablation therapy for heart failure. It is comparable to Relief Cardiovascular as a venture-stage company pursuing a novel transcatheter, device-based intervention that directly targets hemodynamics in chronic heart failure patients.
Broad incumbents
- Edwards Lifesciences: Edwards Lifesciences is a dominant structural heart player (TAVR/sapien, Pascal, and acquired V-Wave interatrial shunt program). It is a broad incumbent with overlapping interest in transcatheter heart failure devices and the resources to compete with or acquire emerging players like Relief Cardiovascular.
- Medtronic: Medtronic is a major cardiovascular device incumbent with CRT, ICD, heart failure diagnostics, and structural heart franchises. It is a broad incumbent that competes in the same heart failure treatment landscape and has the resources to develop or acquire transcatheter preload modulation technologies.
- Abbott: Abbott offers the CardioMEMS HF System, the leading implantable hemodynamic monitoring product for heart failure, along with LVADs (HeartMate 3) and a broad structural heart portfolio. It is a broad incumbent in implantable heart failure diagnostics and therapy, and the most direct large-company competitor in autonomous hemodynamic monitoring.
Emerging players
- Carmat: Carmat is developing a total artificial heart for end-stage biventricular heart failure. While a much more invasive approach than Relief's transcatheter implant, it competes in the broader implantable heart failure therapy landscape and is at a similar early-commercial/advanced-clinical stage.
- BioVentrix: BioVentrix is developing the Revivent less invasive ventricular enhancement system for heart failure. It is an emerging player with partial overlap in the transcatheter/implantable heart failure device category, focused on ventricular remodeling rather than preload modulation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Relief Cardiovascular social profiles
Digital presenceRelief Cardiovascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
Relief Cardiovascular leadership team
Management profileNumber of profiles
Profiles2 records
Relief Cardiovascular funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Relief Cardiovascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Relief Cardiovascular
What does Relief Cardiovascular do?
Relief Cardiovascular develops the Relief System, the world's first transcatheter preload modulating implant for heart failure management. The Class III implantable medical device is delivered minimally invasively into the inferior vena cava and combines autonomous hemodynamic monitoring with permanent venous return modulation to lower renal vein pressures, enhance diuresis and decongestion, and reduce heart failure hospitalizations in diuretic-resistant patients.
Is Relief Cardiovascular a public or private company?
Relief Cardiovascular is a private company. It is classified as venture growth investor backed and is currently operating.
When was Relief Cardiovascular founded?
Relief Cardiovascular was founded in 2022. It employs 11 to 50 people.
Where is Relief Cardiovascular based?
Relief Cardiovascular is headquartered in Costa Mesa, United States, in the North America region.
How does Relief Cardiovascular make money?
One revenue line is on record: transcatheter Implant Sales.
Who are Relief Cardiovascular's main competitors?
Direct peers on record are Corvia Medical, Procyrion, WhiteSwell, Ancora Heart and Axon Therapies. Broad incumbents are Edwards Lifesciences, Medtronic and Abbott. Emerging players are Carmat and BioVentrix.
Does Relief Cardiovascular have an API?
No public API is recorded for Relief Cardiovascular.
What industry is Relief Cardiovascular in?
Relief Cardiovascular's product category is Interventional Cardiology Medical Devices. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAKABAB, Interventional Cardiology (PCI/Structural Heart). Its NAICS code is 339113 and its SIC code is 3841.